10-KPeriod: FY2015

BeOne Medicines Ltd. Annual Report, Year Ended Dec 31, 2015

Filed March 30, 2016For Securities:ONCBEIGF

Summary

BeOne Medicines Ltd. (ONC), a biopharmaceutical company focused on oncology, is in the clinical stage of developing innovative molecularly targeted and immuno-oncology drugs. As of its March 30, 2016, 10-K filing, the company had not yet generated product revenue but was advancing four key clinical-stage drug candidates: BGB-3111 (BTK inhibitor), BGB-A317 (PD-1 inhibitor), BGB-290 (PARP inhibitor), and BGB-283 (RAF dimer inhibitor). The company's strategy centers on its proprietary cancer biology platform, which aims to improve drug discovery by incorporating novel tumor-immune system interaction models. BeOne Medicines highlights its strong R&D team, its strategic positioning in China with potential regulatory advantages, and its focus on developing combination therapies. The company had recently completed an initial public offering (IPO) in February 2016, raising approximately $166.6 million in net proceeds, which it plans to use for ongoing clinical development, R&D, manufacturing facility expansion, and general corporate purposes.

Financial Highlights

43 data points
Beta

Revenue

$8.82M

Net Income

-$57.10M

-647.7% Net Margin

EPS (Diluted)

$-0.52

Total Assets

$116.76M

Cash & Equivalents

$17.87M

Free Cash Flow

-$45.16M

Financial Statements
Beta
Revenue$8.82M
R&D Expenses$58.25M
SG&A Expenses$7.31M
Operating Expenses$65.56M
Operating Income-$56.74M
Net Income-$57.10M
EPS (Basic)$-0.52
Shares Outstanding (Basic)110.60M

Key Highlights

  • 1BeOne Medicines is advancing four clinical-stage drug candidates (BGB-3111, BGB-A317, BGB-290, BGB-283) for cancer treatment, focusing on molecularly targeted therapies and immuno-oncology.
  • 2The company's proprietary cancer biology platform is a key differentiator, designed to improve drug discovery through novel models of tumor-immune system interactions.
  • 3BeOne Medicines completed its Initial Public Offering (IPO) in February 2016, raising approximately $166.6 million in net proceeds to fund ongoing operations and development.
  • 4The company has a significant R&D presence and operational base in China, leveraging potential regulatory advantages and access to a large patient population.
  • 5A key strategic focus is the development of combination therapies using its internal pipeline of drug candidates.
  • 6The company has a collaboration with Merck KGaA for the development and commercialization of BGB-283 (ex-China) and a limited collaboration for BGB-290.
  • 7BeOne Medicines has incurred substantial net losses since inception and anticipates continuing losses in the foreseeable future as it invests heavily in R&D.

Frequently Asked Questions

BeOne Medicines' strategy is to become a leader in discovering and developing innovative molecularly targeted and immuno-oncology drugs for cancer treatment. They leverage a proprietary cancer biology platform to advance a pipeline of drug candidates, with a focus on developing best-in-class monotherapies and combination therapies. A significant part of their strategy includes capitalizing on opportunities within the Chinese market due to its large patient population and potential regulatory advantages.

As of March 2016, BeOne Medicines has four key clinical-stage drug candidates: BGB-3111 (a BTK inhibitor for lymphomas), BGB-A317 (a PD-1 antibody for various solid and blood cancers), BGB-290 (a PARP inhibitor for homologous recombination deficient cancers), and BGB-283 (a RAF dimer inhibitor for cancers with MAPK pathway aberrations).

BeOne Medicines has not generated revenue from product sales to date. Its primary funding sources have been private equity financing and, more recently, the net proceeds from its February 2016 IPO ($166.6 million). The company also receives collaboration revenue from its agreement with Merck KGaA for BGB-283 and BGB-290.

Key risks include the inherent uncertainties in drug development (clinical trial failures, regulatory approval delays), the need for substantial future funding, competition from other pharmaceutical companies, reliance on third parties for manufacturing and clinical trials, intellectual property protection, and regulatory and political risks associated with operating in China. The company also faces risks related to its emerging growth company status and potential PFIC status for U.S. investors.